Jazz's Zepzelca fails late-stage lung cancer trial

June 12, 2026 8:01 AM

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced that its Phase 3 LAGOON trial evaluating Zepzelca (lurbinectedin) in patients with relapsed small ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found